Tg Therapeutics (TGTX) Long-Term Deferred Tax (2025 - 2026)
Tg Therapeutics (TGTX) recorded quarterly Long-Term Deferred Tax of $344.1 million in Q1 2026, down 1.11% quarter-over-quarter from $348.0 million in Q4 2025.
Tg Therapeutics (TGTX) Long-Term Deferred Tax (2025 - 2026) Analysis & Trends
Tg Therapeutics' Long-Term Deferred Tax history runs 2 years deep, the most recent figure standing at $344.1 million for Q1 2026.
- In Q1 2026, Long-Term Deferred Tax changed N/A year-over-year to $344.1 million; the TTM figure through Mar 2026 stood at $344.1 million (changed N/A YoY), while the FY2025 annual figure was $348.0 million, changed N/A from the prior year.
- Long-Term Deferred Tax was $344.1 million for Q1 2026 at Tg Therapeutics, down from $348.0 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $366.6 million in Q3 2025 to a low of $344.1 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Tg Therapeutics | 7.71 Bn | 7.06 Bn | 171.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 344.14 Mn |
| Dec 31, 2025 | 348.00 Mn |
| Sep 30, 2025 | 366.63 Mn |